UTICA, NY--(Marketwired - Mar 11, 2014) - CONMED Corporation (NASDAQ: CNMD) today announced the launch of a new line of products that will be showcased at this year's American Academy of Orthopaedic Surgeons Annual Meeting in New Orleans. The new products, available at exhibit booth #2249, include recent additions to the Y-Knot® all-suture anchor line, a new offering for Hall® battery operated power instruments as well as the latest in High Definition advanced surgical visualization.
"We are proud to introduce this year's line-up of new orthopaedic products to be demonstrated by leading orthopaedic surgeons at AAOS," said Joseph Darling, CONMED's Executive Vice President for Commercial Operations and President of CONMED Linvatec. "These innovative devices, which build upon our existing line of products, are designed to assist surgeons in delivering superior patient outcomes in an affordable manner. We look forward to showcasing their benefits at the AAOS."
Throughout the AAOS meeting, CONMED will host presentations by surgical experts on important current topics in the field of arthroscopic repair incorporating the following new products:
2D-HD Visualization Platform - The new IM-8000 2D-HD platform continues CONMED's reputation for high-quality surgical visualization technology that's both durable and dependable. The new camera head features best-in-class 3-chip CMOS technology that improves the processing of light to create a pure image with exceptional resolution. As with the Company's prior models, the camera head is autoclavable for efficient sterilization. Also on display is the new LS-8000 LED light source which provides improved light sensitivity for clearer visualization. CF-rated for multi-specialty procedures, this newest visualization technology is a versatile and cost-effective solution for hospitals and surgery centers.
SPORTS MEDICINE - ARTHROSCOPY
Arthroscopic Energy System - Designed by RF technology innovators, CONMED's new bi-polar RF Arthroscopic Energy System ("AES") offers a versatile, intuitive design and user interface for arthroscopic ablation, coagulation and dissection. The AES consists of a radio frequency generator, bi-polar probes and optional wired or wireless foot controls. The single-use bi-polar probes are engineered for shoulder, knee, hip and extremity arthroscopy procedures.
D4000 Arthroscopic Resection Unit - The D4000 Arthroscopic shaver blade control unit features a touchscreen display with a customizable preference profile enabling storage and availability of surgeon preferred settings. With plug and play operation and integration with CONMED's fluid pumps, it provides for a seamless clinical experience.
Y-Knot® All-Suture Anchors - CONMED continues to innovate for shoulder arthroscopy with the Y-Knot® Flex System for instability repairs featuring the smallest double-loaded (1.8mm) anchor currently available with curved flexible instrumentation to help surgeons achieve ideal anchor placement. For rotator cuff repairs, Y-Knot® RC anchors are currently the world's only self-punching all-suture anchors. Surgeons find these anchors help simplify techniques, while their small size is designed to improve placement options.
Hall® POWERED INSTRUMENT SYSTEMS
Hall 50™ Powered Instruments - Building upon 50 years of powered instrument engineering expertise, the new Hall 50™ Powered Instrument System is designed for performance, precision and reliability. The lighter, ergonomically-designed handpieces provide a comfortable, high-performance clinical experience. Together with the recently released Hall autoclavable lithium batteries, the instruments deliver dependable, long-lasting power. The unique, multi-tray system also provides hospitals with new levels of sterilization convenience that have already proven valuable to clinicians.
ENHANCE® Bone Void Filler - CONMED is also launching a new tissue form for filling bone voids in orthopaedic surgery. Through the Company's partnership with the Musculoskeletal Transplant Foundation ("MTF"), the new ENHANCE® Demineralized Cortical Fibers Allograft Bone Void Filler offers handling properties comparable to that of synthetic bone void fillers while adding the osteoinductive and osteogenic opportunities of 100% demineralized cortical bone.
CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company's total sales.
Forward Looking Information
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw materials or transportation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.